ConductScience.org, home

Paper41520178

IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity.

Barragán Bravo GA and 22 others. Mol Ther, 2026. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity. Papers, record 41520178. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41520178

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity.
PubMed
Journal
Mol Ther
PubMed
Year
2026
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-10-24
PubMed

Authors23

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Barragán Bravo GAGabriel A
2de la Cerda DADavid A
3Landoni EElisa
4Dholakia KKshiti
5Humeniuk PPiotr
6Caraballo Galva LDLeidy D
7Wang YYing
8Tian GGengwen
9Yang BBoning
10Guo LLinjie
11Wood MSMichael S
12Rios XXavier
13Xu XXin
14Courtney ANAmy N
15Di Pierro EJErica J
16Jacob JJoan
17Li YHYi-Han
18Adaikkalavan AAkshaya
19Watanabe NNorihiro
20Mao SSufeng

Source PubMed

See all 23 authorsDownload CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Receptors, Chimeric AntigenMajor topic
Interleukin-18Major topic
Immunotherapy, AdoptiveMajor topic
Natural Killer T-CellsMajor topic
Humans
Animals
Mice
Interleukin-15
Cell Line, Tumor
Metabolic Reprogramming
Cytotoxicity, Immunologic
Xenograft Model Antitumor Assays

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
R01 CA262250NCI NIH HHSUnited StatesR01CA262250PubMedNIH RePORTER
R01 CA247436NCI NIH HHSUnited StatesR01CA247436PubMedNIH RePORTER
P50 CA126752NCI NIH HHSUnited StatesP50CA126752PubMedNIH RePORTER
P30 CA125123NCI NIH HHSUnited StatesP30CA125123PubMedNIH RePORTER
S10 OD028671NIH HHSUnited StatesS10OD028671PubMedNIH RePORTER

Download CSV of grants

References104

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119637196IL-18 skews the invariant NKT-cell population via autoreactive activation in atopic eczema.Eur J Immunol2009https://conductscience.org/library/papers/19637196PubMed
222455463clusterProfiler: an R package for comparing biological themes among gene clusters.OMICS2012https://conductscience.org/library/papers/22455463PubMed
338168996IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases.Nat Biotechnol2024https://conductscience.org/library/papers/38168996PubMed
436520914Multidimensional control of therapeutic human cell function with synthetic gene circuits.Science2022https://conductscience.org/library/papers/36520914PubMed
527183388CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.J Clin Invest2016https://conductscience.org/library/papers/27183388PubMed
640864984CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia.Blood2025https://conductscience.org/library/papers/40864984PubMed
734376537Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming.Clin Cancer Res2021https://conductscience.org/library/papers/34376537PubMed
833616889Naxitamab: First Approval.Drugs2021https://conductscience.org/library/papers/33616889PubMed
927530312Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.Hum Gene Ther2017https://conductscience.org/library/papers/27530312PubMed
1033499253Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.Int J Mol Sci2021https://conductscience.org/library/papers/33499253PubMed
1124227677featureCounts: an efficient general purpose program for assigning sequence reads to genomic features.Bioinformatics2014https://conductscience.org/library/papers/24227677PubMed
1233428453Cytokine Regulation and Function in T Cells.Annu Rev Immunol2021https://conductscience.org/library/papers/33428453PubMed
1318978797Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.Nat Med2008https://conductscience.org/library/papers/18978797PubMed
1421990318Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression.Cancer Res2011https://conductscience.org/library/papers/21990318PubMed
1531863285A comprehensive pathway map of IL-18-mediated signalling.J Cell Commun Signal2020https://conductscience.org/library/papers/31863285PubMed
1636175679KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape.Nat Med2022https://conductscience.org/library/papers/36175679PubMed
1730778252Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade.Nat Immunol2019https://conductscience.org/library/papers/30778252PubMed
1840604285Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery.Nature2025https://conductscience.org/library/papers/40604285PubMed
1938579288IL-18-secreting multiantigen targeting CAR T cells eliminate antigen-low myeloma in an immunocompetent mouse model.Blood2024https://conductscience.org/library/papers/38579288PubMed
2036347021Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy.Blood2023https://conductscience.org/library/papers/36347021PubMed

See all 104 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn Papers
42183670CAR-iNKT cells for cancer therapy: a comprehensive review of engineering, mechanisms, and clinical progress.Immunotherapy2026https://conductscience.org/library/papers/42183670

Source PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CASP9842PubTator's text mininghttps://conductscience.org/library/genes/842NCBI Gene
IL153600PubTator's text mininghttps://conductscience.org/library/genes/3600NCBI Gene
IL183606PubTator's text mininghttps://conductscience.org/library/genes/3606NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41520178

GET https://conductscience.org/api/papers/v1/41520178/authors?page=2